Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Apr;57(4):561-568.
doi: 10.1002/mus.26052. Epub 2018 Feb 2.

3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia

Donald B Sanders  1 , Vern C Juel  1 , Yadollah Harati  2 , A Gordon Smith  3 , Amanda C Peltier  4 , Tessa Marburger  5 , Jau-Shin Lou  6 , Robert M Pascuzzi  7 , David P Richman  8 , Tai Xie  9 , Valentin Demmel  10 , Laura R Jacobus  11 , Kathy L Aleš  11 , David P Jacobus  11 ; Dapper Study Team
Affiliations
Randomized Controlled Trial

3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia

Donald B Sanders et al. Muscle Nerve. 2018 Apr.

Abstract

Introduction: 3,4-diaminopyridine has been used to treat Lambert-Eaton myasthenia (LEM) for 30 years despite the lack of conclusive evidence of efficacy.

Methods: We conducted a randomized double-blind placebo-controlled withdrawal study in patients with LEM who had been on stable regimens of 3,4-diaminopyridine base (3,4-DAP) for ≥ 3 months. The primary efficacy endpoint was >30% deterioration in triple timed up-and-go (3TUG) times during tapered drug withdrawal. The secondary endpoint was self-assessment of LEM-related weakness (W-SAS).

Results: Thirty-two participants were randomized to continuous 3,4-DAP or placebo groups. None of the 14 participants who received continuous 3,4-DAP had > 30% deterioration in 3TUG time versus 72% of the 18 who tapered to placebo (P < 0.0001). W-SAS similarly demonstrated an advantage for continuous treatment over placebo (P < 0.0001). Requirement for rescue and adverse events were more common in the placebo group.

Discussion: This trial provides significant evidence of efficacy of 3,4-DAP in the maintenance of strength in LEM. Muscle Nerve 57: 561-568, 2018.

Keywords: 3,4-diaminopyridine; ELS; Eaton-Lambert syndrome; LEMS; LES; Lambert-Eaton myasthenia; Lambert-Eaton myasthenic syndrome; Lambert-Eaton syndrome; amifampridine; clinical trial; efficacy; timed up-and-go.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study design schematic. 3,4‐DAP, 3,4‐diaminopyridine base.
Figure 2
Figure 2
CONSORT (Consolidated Standards of Reporting Trials) diagram. 3,4‐DAP, 3,4‐diaminopyridine base.
Figure 3
Figure 3
Percentage change from baseline in 3TUG test at 2 h after dosing versus time, by treatment group. 3TUG, triple timed up‐and‐go. *P < 0.05, **P < 0.01, one‐way ANCOVA, with the baseline 3TUG as the covariate. 3,4‐DAP, 3,4‐diaminopyridine base; A, afternoon; ANCOVA, analysis of covariance; 3TUG, triple timed up ‐and ‐go; E, evening; M, morning.
See this image and copyright information in PMC

Comment in

References

    1. Juel VC, Sanders DB. Lambert‐Eaton myasthenic syndrome In: Engel AG, editor. Myasthenia gravis and myasthenic disorders, 2nd ed. Oxford, United Kingdom: Oxford University Press; 2015. p 156–172.
    1. Deenen JCW, Horlings CGC, Verschuuren JJGM, Verbeek ALM. The edipemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscular Dis 2015;2:73–85. - PubMed
    1. Abenroth DC, Smith AG, Greenlee JE, Austin SD, Clardy SL. Lambert–Eaton myasthenic syndrome: epidemiology and therapeutic response in the national veterans affairs population. Muscle Nerve 2017;56(3):421–426. - PubMed
    1. Lang B, Waterman S, Pinto A, Jones D, Moss F, Boot J, et al The role of autoantibodies in Lambert‐Eaton myasthenic syndrome. Ann N Y Acad Sci 1998;841:596–605. - PubMed
    1. Lundh H, Nilsson O, Rosén I. Novel drug of choice in Eaton‐Lambert syndrome. J Neurol Neurosurg Psychiatry 1983;46:684–687. - PMC - PubMed

Publication types